South Carolina Patent of the Month – January 2023

With the advent of globalization and increased international travel, it is crucial to have a solution in place to address the rapid spread of diseases. The coronavirus disease (COVID-19) outbreak is a prime example of how infectious diseases can pose a significant public health threat. COVID-19 is highly contagious and can be spread by asymptomatic carriers, making it difficult to control the spread of the virus.

At this stage, we still do not have a reliable antiviral treatment for COVID-19, nor can we anticipate the next public health threat. With uncertainty like this, developing a vaccine platform technology that can quickly and effectively train the immune system to recognize the pathogen could be the difference between an expedient response and another global shutdown. Orbis Health Solutions, LLC is addressing these challenges by utilizing the antigen presenting process in the human immune system.

Historically, it has been difficult to produce vaccines that can effectively and consistently produce a sustained immunogenic response in a host. Most vaccines utilize killed or weakened pathogens or isolated peptides, which are difficult to produce en masse. In contrast, nucleic acid sequences are comparatively simple to produce en masse and can be quickly duplicated. Orbis Health Solutions is leveraging this advantage by using nucleic acid sequences to produce vaccines that can be rapidly scaled up and produced for widespread use.

Orbis Health Solutions’ innovative approach to developing vaccines is poised to make a significant impact in the fight against infectious diseases. The use of nucleic acid sequences to produce vaccines that can be quickly and easily produced in mass will make it possible to address public health threats in a timely and effective manner. With the growing threat of infectious diseases and the need for treatments and cures, Orbis Health Solutions is an essential player in the fight against these global public health threats.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts